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Abstract
Background: Amyloid- is recognized as the major constituent of senile plaque found in subjects
with Alzheimer's disease. However, there is increasing evidence that in a physiological context
amyloid- may serve as regulating apolipoprotein, primarily of the triglyceride enriched
lipoproteins. To consider this hypothesis further, this study utilized an in vivo immunological
approach to explore in lipogenic tissue whether amyloid- colocalizes with nascent triglyceride-
rich lipoproteins.
Results: In murine absorptive epithelial cells of the small intestine, amyloid- had remarkable
colocalization with chylomicrons (Manders overlap coefficient = 0.73 ± 0.03 (SEM)), the latter
identified as immunoreactive apolipoprotein B. A diet enriched in saturated fats doubled the
abundance of both amyloid- and apo B and increased the overlap coefficient of the two proteins
(0.87 ± 0.02). However, there was no evidence that abundance of the two proteins was
interdependent within the enterocytes (Pearson's Coefficient < 0.02 ± 0.03), or in plasma
(Pearson's Coefficient < 0.01).
Conclusion: The findings of this study are consistent with the possibility that amyloid- is secreted
by enterocytes as an apolipoprotein component of chylomicrons. However, secretion of amyloid-
 appears to be independent of chylomicron biogenesis.
Background
Amyloid- is recognized as the principal protein in senile
plaques in subjects with Alzheimer's disease (AD) [1].
Generated from the slicing of amyloid precursor protein
(APP) by secretases, the synthesis of amyloid- can be
differentially modulated by cellular lipid homeostasis.
Studies in cell culture and in vivo suggest that cholesterol
inhibits amyloid- biogenesis [2-4], although this effect
may be dependent on the distribution of free and esteri-
fied cholesterol within the plasma membrane and within
lipid rafts [5]. In contrast, in vivo studies found that
chronic ingestion of diets enriched in saturated-fats (SFA)
had a potent stimulatory effect on enterocytic amyloid-
abundance [6].
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Several lines of evidence suggest that one physiological
role for amyloid- is as a regulating apolipoprotein, par-
ticularly of the triglyceride-rich lipoproteins (TRL's).
Koudinov et al reported that amyloid- is secreted by
hepatocytes as a lipoprotein complex [7]. Significant
plasma abundance of amyloid- was also found in the
TRL fraction of control subjects and amyloid- enrich-
ment in TRL's was evident in subjects with AD, or with
mild cognitive impairment [8]. Ingestion of a lipid rich
meal also causes a transient increase in plasma of soluble
APP, concomitant with postprandial lipaemia [9] and
when injected intravenously associated with TRL-emul-
sions, amyloid- increased uptake in fat-rich tissues rela-
tive to liver [10].
The  APP is expressed on the plasma membrane of a
number of tissues including lipogenic organs such as liver
[6]. Proteolytic cleavage of APP generally results in the
extracellular release of amyloid- which is then chaper-
oned by transporter proteins [11-14]. However, hydro-
phobic domains within amyloid- [15] results in rapid
folding of amyloid- that make it unlikely to readily asso-
ciate with lipoproteins already secreted into circulation.
Rather, immunhistochemistical studies show amyloid-
abundance within the perinuclear region of hepatocytes
and absorptive epithelial cells of the small intestine
[4,6,7,16], suggesting that amyloid- may form part of the
primordial lipoprotein during the lipidation process.
Consistent with the latter, using a phage display Nelson
and Alkon showed that amyloid- bound tightly with sev-
eral apolipoproteins found commonly with TRL [17]. To
further consider the possibility that amyloid- becomes
associated with nascent lipoproteins, in this study we uti-
lized sensitive three-dimensional (3D) immunofluores-
cent (IF) microscopy to explore if enterocytic abundance
of amyloid- is associated with chylomicrons. Apolipo-
protein (apo) B, an obligatory component of TRL secreted
by intestine and liver, was used as a marker of enterocytic
chylomicron distribution and plasma abundance of TRL.
Materials and methods
Diet and animals
The protocols described in this study were approved by an
accredited National Health and Medical Research Council
of Australia Animal Ethics Committee (Curtin University
Animal Experimentation and Ethics Committee Reference
number R02-07). Six-week-old female C57BL/6J mice
(Animal resources centre, Murdoch, Western Australia)
were divided randomly into a low-fat (LF) or saturated
fatty acid (SFA) diet group. Low fat mice were given chow
that contained 3.6% (w/w) as unsaturated fat and 0.4%
SFA (AIN93M, Specialty Feeds, Western Australia). The
SFA enriched chow contained 12.9% (w/w) as saturated
fats and 7.4% as unsaturated oils (SF07-50, Specialty
feeds, Western Australia). Both diets were free of choles-
terol. Digestible energy for LF and SFA feed were 15.1 MJ/
kg and 18.8 MJ/kg respectively and feed was available ad
libitum. After three-months of dietary intervention, mice
were sacrificed by pentobarbital injection. The small intes-
tine was isolated and flushed with chilled phosphate buff-
ered saline (PBS, pH 7.4). A 2 cm segment of the small
intestine distal to the duodenum was fixed in 4% parafor-
maldehyde for a minimum of 24 h, processed and longi-
tudinal segments embedded in paraffin wax. Serial
sections of 5 m thick were cut on microtome and
mounted on silanised slides for histology and immun-
ofluorescence microscopy.
Antibodies
Anti-apo B, anti Golgi-apparatus (anti-Golgi 58 K), anti-
rabbit IgG with Alexa488, and streptavidin-Alexa546 were
obtained from Invitrogen (Melbourne, Victoria, Aus-
tralia). Anti-rabbit IgG biotin conjugate was obtained
from DAKO (Glostrup, Denmark). Rabbit anti-human
amyloid- was obtained from Chemicon International
(Temecula, California, United States).
Double-immunofluorescent labelling
An established double IF labelling method was utilized as
previously described [18]. Cross reactivity was prevented
using a biotin-avidin amplification technique micros-
copy. The concentration of the primary antibody used
with biotin-avidin amplification is substantially below
the threshold required for detection by standard IF and
does not interfere with detection of the second protein.
Anti-amyloid- (1:1000) was added to sections overnight
at 4°C, followed by addition of goat anti-rabbit IgG with
biotin (1:200) for 1 h at room temperature. Thereafter,
anti-Golgi-apparatus (1:10) was added overnight at 4°C.
Immunofluorescence was detected by streptavidin-
Alexa546 (1:100) and anti-rabbit IgG with Alexa488
(1:100) for amyloid- and Golgi-apparatus respectively.
Cell nuclei were detected using DAPI and slides were
mounted using anti-fade mounting medium. The same
method was used to achieve double apo B and Golgi-
apparatus staining by substituting the anti-amyloid-
with anti-apo B (1:400).
Image capture
Digital images were captured using AxioCam mRM and
ApoTome on a Zeiss Axiovert 200 M inverted microscope
and visualized with Plan-NeoFluar lenses (Carl Zeiss,
Oberkochen, Germany). Excitation and emission were
achieved by using filters 43 (Ex BP545/25, beam splitter
FT570 and Em BP605/70) and 38 (Ex BP470/40, beam
splitter FT495 and Em BP525/50) to determine fluores-
cence of Alexa546 and Alexa488 respectively. Filter 49 (Ex
G365, beam splitter FT 395 and Em BP445/50) was used
to detect nuclei stain DAPI. Individual channels areLipids in Health and Disease 2009, 8:46 http://www.lipidworld.com/content/8/1/46
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devoid of fluorescence from other emission sources and
are therefore clear of bleed-through.
Three-dimensional images were captured using the
ApoTome optical sectioning mode which allows the crea-
tion of a 3D image based on the 'stacking' of consecutive
2D images. Each 3D image consisted from 8-10 2D
images, and the axial distance of Z-stack was 0.5 m for
200×. There were 6 animals per group with a minimum of
40 images per mouse used for analysis. Fluorescent inten-
sity and area were determined using the measurement and
colocalization module available on AxioVision v4.7.1
software (Carl Zeiss, Oberkochen, Germany).
Quantification of fluorescent intensity and colocalization
There are several algorithms capable of achieving meas-
ures of colocalization or association via measurement of
fluorescent pixel spatial orientation and pixel intensity.
The Pearson's correlation coefficient (r) is a commonly
used quantitative estimate of association (abundance) for
proteins [19]. However, as Pearson's correlation is a meas-
ure of variance from the mean pixel intensity, it does not
provide information of the area of overlap. A modifica-
tion to Pearson's correlation coefficient developed by
Manders et al (1993) eliminates the average grey values
from the Pearson's formula to allow the quantification of
overlapping pixels from each channel [19]. The degree of
colocalization for the proteins is positively related to the
Manders coefficient, known commonly as the 'overlap
coefficient' (OC). The AxioVision software utilizes an
automated procedure based on spatial statistics to deter-
mine Pearson's correlation coefficient and Manders OC,
thereby avoiding selection bias by manual selection meth-
ods.
Western blotting for plasma apolipoprotein B
Plasma samples were separated on NuPAGE 3-8% Tris-
acetate gels (EA03752BOX, Invitrogen, Victoria, Aus-
tralia) at 150 V (Biorad Model 20012.0) for 1 hr. Gels
were then electrotransferred to PVDF membranes
(PV4HY00010, Osmonics Inc, Minnesota U.S.A) at 40 V
for 1 hr and blocked in 10% skim milk (in TBST) over-
night at 4°C. The membranes were incubated with poly-
clonal rabbit anti-human apo B 1:100 (Q0497,
Dakocytomation, Glostrup, Denmark), and then with
donkey anti-rabbit immunoglobulin G (IgG) horseradish
peroxidase (HRP) (Na934V, Amersham Bioscience, Buck-
inghamshire, UK). Proteins were detected using enhanced
chemiluminescence reagent (ECL™) western blotting
analysis system (RPN2108, Amersham Bioscience, Buck-
inghamshire, UK). Membranes were exposed to high per-
formance chemiluminescence film (Amersham
Hyperfilm™, Amersham Bioscience, Buckinghamshire,
UK) and developed in an AGFA-Gevaert Rapidoprint X-
Ray Developer (Septestraat, Belgium). Apo B48 bands
were identified and quantified by densitometry against
purified apo B48 protein of known mass (550 kDa for apo
B-100 and 260 kDa for apo B48).
Amyloid-beta ELISA
Plasma amyloid- 40/42 levels were measured using com-
mercially available ELISA kits (Biosource, Camarillo CA).
Statistics
Enterocytic colocation of amyloid- with apo B was deter-
mined by an automated procedure based on spatial statis-
tics to determine Pearson's correlation coefficient and
Manders OC (AxioVision 4.0). The association between
total apo B, apo B48, and apo B100 with total amyloid-,
amyloid-40 and amyloid-42 were examined using Pear-
son's and Spearman's correlation. Spearman's correlation
was used when the assumptions of the analysis were vio-
lated due to the presence of outliers. P-values less than 5%
were considered as statistically significant and the data
was analysed using SPSS version 17.0.
Results
Enterocytic chylomicrons were detected by determining
the distribution of apo B, an obligatory structural compo-
nent of chylomicrons. Significant amounts of amyloid-
and apo B were found to be enriched within the perinu-
clear region of cells. Amyloid- and apo B colocalized
with the Golgi-apparatus, towards the basolateral surface
of the cell and within the lacteals (Figure 1). The patterns
of distribution for amyloid- and apo B remained essen-
tially the same in LF and SFA fed mice (Figure 2), however
abundance of each protein more than doubled in SFA fed
mice compared to LF fed animals (Table 1, columns 1 and
2).
The colocalization of enterocytic amyloid- and apo B
was expressed as the OC (Manders overlap coefficient).
The relative abundance of amyloid- and apo B in LF and
in SFA fed mice, given as mean densitometric sum. In LF
mice, approximately 73% of immunodetectable amyloid-
 colocated with apo B, but in SFA mice this was signifi-
cantly increased (p < 0.05) to nearly 87% (Table 1, col-
umns 3 and 4). Figure 2 shows the extent of colocalisation
in three dimensions of amyloid- relative to apo B under
high magnification.
To explore if abundance of the amyloid- was inter-
dependent with TRL biogenesis and secretion, correlation
analysis with apo B was determined within enterocytes
and in plasma respectively. Pearson's correlation analysis
found that just 2% of amyloid- and apo B fluorescent
intensities were positively associated in enterocytes of LF
or any of the SFA fed mice (table 1). Similarly, in plasma
there was no evidence that the principal isoforms of amy-Lipids in Health and Disease 2009, 8:46 http://www.lipidworld.com/content/8/1/46
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loid- (amyloid-40 and 42) were associated with intesti-
nal or hepatic apo B lipoproteins (figure 3).
Discussion
In this study the distribution and abundance of amyloid-
 and apo B were detected in small intestinal enterocytes
using an established double-labeled avidin-biotin IF
microscopy technique [18]. Amyloid- and chylomicron-
apo B were remarkably colocalized in enterocytes, consist-
ent with release of amyloid- as a lipoprotein complex
[7]. We also confirm that chronic consumption of SFA
increases enterocytic amyloid- and now show that this
occurrence is concomitant with a substantially greater
abundance of enterocytic apo B [6]. However, there was
no evidence from this study that the biogenesis of amy-
loid- and apo B are inter-dependent based on Pearson's
correlation analysis within enterocytes and in plasma.
The biosynthesis of chylomicrons occurs in a multi-step
process that requires the progressive lipidation of apo B an
obligatory structural component of primordial lipopro-
teins secreted by the small intestine [20,21]. A number of
proteins are reported to associate with nascent chylomi-
crons prior to secretion, including apo A-I, A-IV, apo J, apo
D, apo E and small molecular weight proteins such as apo
C-II. Nascent chylomicrons are then transported via the
Golgi-apparatus to the basolateral membrane and
secreted into lymphatics. The results from this study sug-
gest that amyloid- is secreted from small intestinal ente-
rocytes as an apolipoprotein of chylomicrons.
Immunoreactivity for amyloid- and apo B was found
selectively within the ER/Golgi-apparatus and not on the
plasma membrane. The findings are consistent with bio-
genesis of amyloid- at the ER and translocation to pri-
mordial lipoproteins, rather than as a consequence of 
APP processing. Similar results in hepatocyte cultures with
secretion of amyloid- also occurring exclusively as a lipo-
protein complex [7].
Dietary SFA promote chylomicron biogenesis by stimulat-
ing apo B lipidation [22,23], an essential step to avoid
post-translational degradation by intracellular proteases
[24]. Greater lipid substrate availability (as a result of SFA
ingestion) reduces the proportion of apo B that would
otherwise be degraded. The SFA dietary intervention used
in this study essentially doubled enterocytic apo B and a
similar increase in amyloid- abundance was observed.
Enterocytic amyloid- and apolipoprotein B colocalizes with Golgi-apparatus under LF and SFA feeding Figure 1
Enterocytic amyloid- and apolipoprotein B colocalizes with Golgi-apparatus under LF and SFA feeding. The 
images depict the colocalization of Golgi-apparatus with amyloid- (columns 1 and 2) and apo B (columns 3 and 4) in low-fat 
(LF) and saturated fat (SFA) fed mice. The upper row shows small intestinal villi at low magnification (mag) in two dimension, 
whilst the lower frames depicts enterocytes at high magnification in three dimensions. Amyloid- as indicated in red, apo B as 
yellow, Golgi-apparatus as green, and nuclei as blue pixels. Where overlap of pixels occurs between amyloid- (red) and Golgi-
apparatus (green), an orange colour prevails. Similarly, the colocalization of apo B (yellow) with Golgi-apparatus (green) gener-
ates lime colour. Perinuclear (white arrow) and lamina propria (Lp) presence of amyloid- and respective proteins are shown. 
Lu labels the lumen that represents the apical surface of the cell and Lp (lamina propria) is the direction of lacteals where lipo-
proteins are expelled via exocytosis. Scale: bar (2D images) = 10 m; grid (3D images) = 3.63 m.Lipids in Health and Disease 2009, 8:46 http://www.lipidworld.com/content/8/1/46
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However, the mechanisms by which SFA stimulate amy-
loid- abundance and association with nascent chylomi-
crons are less clear. Saturated-FA may have a broader non-
specific effect on enterocytic protein synthesis and consist-
ent with the possibility of substrate driven biogenesis,
Patil (2006) [25] found in neurons treated with palmitic
acid resulted in increased upregulation BACE, a key
enzyme complex involved in the processing of   APP.
Alternatively, amyloid- is an amphiphatic protein with a
C-terminal domain that avidly binds with negatively
charged hydrophobic lipids [15]. Increased substrate
availability and synergistic lipidation of amyloid- and
apo B may promote the incorporation of amyloid- into
nascent chylomicrons and subsequently stimulate further
synthesis of the proteins.
The SFA induction and secretion of enterocytic amyloid-
may be important in the context of AD risk. Recent studies
suggest that blood-to-brain delivery of amyloid- may
contribute to amyloidosis, particularly when the concen-
tration of circulating amyloid- is chronically elevated
[26-28]. This study suggest that SFA's increase synthesis
and secretion of TRL associated amyloid- concomitant
with deterioration in blood-brain barrier integrity [29].
Indeed, the hypothesis is supported by studies in trans-
genic mice that over-express amyloid-. In  APP/preseni-
lin 1 transgenic mice, the plasma concentration correlated
with secretion rates into blood of TRL's, which was
increased 3-8 fold above wild-type mice [27]. Moreover,
there was a positive association between plasma TRL-amy-
loid- secretion with onset of cerebrovascular and paren-
chymal amyloidosis [29].
Conclusion
In this study, evidence in vivo that amyloid- is secreted
as a chylomicron complex and is stimulated by dietary
SFA's is presented. Exploring this phenomenon in the
context of plasma amyloid- homeostasis and lipoprotein
kinetics may provide insight into the putative association
of high-fat diet with AD risk.
Enterocytic colocalization of amyloid- with apo B under LF and SFA feeding Figure 2
Enterocytic colocalization of amyloid- with apo B under LF and SFA feeding. The enterocytic colocalization of 
amyloid- (A) with apolipoprotein B (apo B) in low-fat (LF) and saturated fat (SFA) fed mice is shown in three dimensions. 
The inset images depict the separate channel view for A and apo B respectively. Amyloid- is seen in red pixels, apo B as yel-
low and nuclei as blue. The perinuclear region (white arrow) and lacteal (Lp) orientation of enterocytes is indicated. Lu labels 
the lumen that represents the apical surface of the cell and Lp (lamina propria) is the direction of lacteals where lipoproteins 
are expelled via exocytosis. Scale: bar (2D inset images) = 10 m; grid (3D images) = 3.63 m.
Table 1: Effect of SFA feeding on concentration and colocalization of enterocytic amyloid- with apo B.
Apo B* Amyloid-* Overlap Coefficient Pearson's Coefficient
Mean SEM Mean SEM Mean SEM Mean SEM
LF 7013 790 5403 404 0.730 0.033 0.020 0.027
SFA 15840^ 1812 13224^ 1002 0.872^ 0.022 0.015 0.023
*Mean enterocytic pixels value is expressed as mean densitometric sum and standard error of mean (SEM).
^Statistical significance was observed between LF and SFA groups with a p-value of at least less than 5%.Lipids in Health and Disease 2009, 8:46 http://www.lipidworld.com/content/8/1/46
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